Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer.

Maria Ornella Nicoletto,Alessandra Baldoni, Francesco Cavallin,Andrea Grego,Cristina Falci,Margherita Nardin,Enzo Mammano,Eleonora Lai,Valter Torri

Therapeutic advances in medical oncology（2023）

引用 0|浏览12

暂无评分

摘要

Receiving PLD-Ox before PARPi may improve prognosis in platinum-sensitive advanced OC patients and may provide advantages in the BRCA-mutated subgroup.

查看译文

关键词

ovarian cancer,parp inhibitor,oxaliplatin,brca-mutated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要